pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 23·1 min read
save

Trump nominates former deputy surgeon general Erica Schwartz as CDC director, testing MAHA influence

Apr 23, 2026·read at Endpoints ↗RegulatoryNeutral

President Trump has announced Erica Schwartz, a former deputy surgeon general, as the new CDC director. Schwartz is known for supporting vaccination and is seen as a traditional public‑health choice.

The CDC leadership vacancy has persisted since August when the previous director, Susan Monarez, was removed after clashes with Health and Human Services Secretary Robert F. Kennedy Jr. Schwartz steps into the role amid ongoing political tension.

Observers note that Schwartz’s independence from Kennedy’s agenda will be closely watched, as it could affect the influence of the MAHA movement on federal health policy. The appointment will be discussed on a live broadcast later today, featuring analysts who will examine its implications for vaccine strategy and public‑health trust.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Post-Hoc Live: MAHA, the new Trump CDC pick and RFK's vaccine agenda”

read at Endpoints ↗
224 words · retrieved Apr 26
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
AGENUS INC
topics
Vaccine2Vaccines

related stories

  • May 11Animal skin disease confirmed in clusters of European men who have sex with menSTAT
  • May 8Opinion: I’m fighting misinformation online. False hantavirus claims follow a now-familiar playbookSTAT
  • May 6STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy fieldSTAT
  • May 4Federal court blocks mailing of mifepristoneSTAT
  • May 2Opinion: What do medical students think about their education?STAT